Jeffrey Millard
About Jeffrey Millard
Jeffrey Millard is an Associate Director of Antibody Drug Substance Development at Arcus Biosciences, with over 20 years of experience in commercial biologics manufacturing. He has held various engineering roles at notable companies, including Amgen, MedImmune, and AveXis, and has contributed to significant projects in process engineering and facility expansion.
Work at Arcus Biosciences
Jeffrey Millard serves as the Associate Director of Antibody Drug Substance Development at Arcus Biosciences. He has held this position since 2021, contributing to the development of antibody drug substances. His role involves overseeing various aspects of the drug development process, ensuring that the production meets industry standards and regulatory requirements.
Previous Experience in Biologics Manufacturing
Millard has over 20 years of engineering experience in commercial biologics manufacturing. His career includes significant roles at various companies. He worked at Eltron Research & Development as a Research Technician from 1996 to 1998, and at Amgen in multiple capacities, including Senior Plant Engineer, Senior Process Engineer, and Principal Process Engineer from 2002 to 2015. He also served as Sr. Manager MS&T at MedImmune and AveXis, Inc. from 2016 to 2021.
Education and Expertise
Jeffrey Millard earned a Bachelor's degree in Chemical Engineering from the University of Colorado at Boulder, completing his studies from 1992 to 1996. His educational background laid the foundation for his extensive career in engineering within the biologics manufacturing sector, focusing on process development and scale-up strategies.
Achievements in Process Development
Millard has successfully scaled-up an upstream monoclonal antibody (mAb) process during transfers between commercial manufacturing sites. He provided design review and operational support for a $65 million cell culture facility expansion. Additionally, he supported a $25 million capital project as a subject matter expert in process engineering and led teams for various microbial and mammalian processes.
Contributions to Regulatory Submissions
In his career, Millard has authored and reviewed sections of Biologics License Applications (BLA) and supplemental BLAs (sBLA) related to Chemistry, Manufacturing, and Controls (CMC). He served as the MS&T process lead for a commercial mAb process during process performance qualification, demonstrating his expertise in regulatory compliance and product development.